文献速递MDS 与骨髓增殖性肿瘤白血病

选择性口服Janus激酶-2(JAK2)抑制剂fedratinib在骨髓纤维化且治疗前血小板计数低的患者中的安全性和疗效

Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts.
PubMed 文献 · Br J Haematol · 2022-04-27

本文基于JAKARTA和JAKARTA2试验,评估fedratinib 400 mg/天在基线血小板50至<100×10^9/L的骨髓纤维化患者中的疗效与安全性。低血小板队列与高血小板队列的脾脏缓解率和症状缓解率均无显著差异,低血小板队列新发或加重血小板减少更常见但无严重事件。作者认为该剂量安全有效且无需初始剂量调整。

要点

  • JAKARTA中低血小板队列24周脾脏缓解率36% vs 高血小板队列49%(p=0.37),无显著差异。
  • JAKARTA2中低血小板队列24周脾脏缓解率36% vs 高血小板队列28%(p=0.41),无显著差异。
  • 低血小板队列新发或加重血小板减少44% vs 高血小板队列9%,无严重血小板减少事件。

核心结论

  • fedratinib 400 mg/天在骨髓纤维化且治疗前血小板计数低的患者中安全有效,这些患者无需初始剂量调整。

研究设计与样本

  • 基于3期安慰剂对照JAKARTA试验(JAK抑制剂初治骨髓纤维化)和2期单臂JAKARTA2试验(既往接受ruxolitinib治疗)分析fedratinib 400 mg/天的疗效与安全性。
  • JAKARTA中低血小板队列(基线血小板50至<100×10^9/L)14/96例(15%),JAKARTA2中33/97例(34%)。

主要发现

  • 24周时,JAKARTA中低血小板队列与高血小板队列(基线血小板≥100×10^9/L)脾脏缓解率分别为36% vs 49%(p=0.37),无显著差异。
  • JAKARTA2中低血小板队列与高血小板队列24周脾脏缓解率分别为36% vs 28%(p=0.41),无显著差异。
  • 低血小板队列与高血小板队列的症状缓解率也无统计学差异。
  • 新发或加重血小板减少在低血小板队列为44%,高血小板队列为9%,但无严重血小板减少事件。
  • 血小板减少通常通过剂量调整管理,仅3/48例低血小板患者因血小板减少停用fedratinib。

临床怎么用

  • 作者认为fedratinib 400 mg/天对骨髓纤维化且治疗前血小板计数低的患者安全有效,无需初始剂量调整。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fedratinib, an oral Janus kinase-2 (JAK2) inhibitor, is approved for patients with myelofibrosis (MF) and platelet counts ≥50 × 109 /l, based on outcomes from the phase 3, placebo-controlled JAKARTA trial in JAK-inhibitor-naïve MF, and the phase 2, single-arm JAKARTA2 trial in patients previously treated with ruxolitinib. We evaluated the efficacy and safety of fedratinib 400 mg/day in patients with baseline platelet counts 50 to <100 × 109 /l ("Low-Platelets" cohorts), including 14/96 patients (15%) in JAKARTA and 33/97 (34%) in JAKARTA2. At 24 weeks, spleen response rates were not significantly different between the Low-Platelets cohort and patients with baseline platelet counts ≥100 × 109 /l ("High-Platelets" cohort), in JAKARTA (36% vs. 49%, respectively; p = 0.37) or JAKARTA2 (36% vs. 28%; p = 0.41). Symptom response rates were also not statistically different between the Low- and High-Platelets cohorts. Fedratinib was generally well-tolerated in both platelet-count cohorts. New or worsening thrombocytopaenia was more frequent in the Low-Platelets (44%) versus the High-Platelets (9%) cohort, but no serious thrombocytopaenia events occurred. Thrombocytopaenia was typically managed with dose modifications; only 3/48 Low-Platelets patients discontinued fedratinib due to thrombocytopaenia. These data indicate that fedratinib 400 mg/day is safe and effective in patients with MF and low pretreatment platelet counts, and no initial fedratinib dose adjustment is required for these patients.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Harrison CN, Schaap N, Vannucchi AM, et al. Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts. Br J Haematol. 2022. PMID: 35476316. doi:10.1111/bjh.18207

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。